This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly
diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The
participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a
first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm
D) conventional chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute